Literature DB >> 33751034

Targeted delivery of protein arginine deiminase-4 inhibitors to limit arterial intimal NETosis and preserve endothelial integrity.

Roberto Molinaro1,2, Mikyung Yu3, Grasiele Sausen1, Colette A Bichsel4, Claudia Corbo3,5, Eduardo J Folco1, Gha Young Lee3, Yuan Liu3, Yevgenia Tesmenitsky1, Eugenia Shvartz1, Galina K Sukhova1, Frederik Kloss1, Kevin J Croce1, Omid C Farokhzad3, Jinjun Shi3, Peter Libby1.   

Abstract

AIMS: Recent evidence suggests that 'vulnerable plaques', which have received intense attention as underlying mechanism of acute coronary syndromes over the decades, actually rarely rupture and cause clinical events. Superficial plaque erosion has emerged as a growing cause of residual thrombotic complications of atherosclerosis in an era of increased preventive measures including lipid lowering, antihypertensive therapy, and smoking cessation. The mechanisms of plaque erosion remain poorly understood, and we currently lack validated effective diagnostics or therapeutics for superficial erosion. Eroded plaques have a rich extracellular matrix, an intact fibrous cap, sparse lipid, and few mononuclear cells, but do harbour neutrophil extracellular traps (NETs). We recently reported that NETs amplify and propagate the endothelial damage at the site of arterial lesions that recapitulate superficial erosion in mice. We showed that genetic loss of protein arginine deiminase (PAD)-4 function inhibited NETosis and preserved endothelial integrity. The current study used systemic administration of targeted nanoparticles to deliver an agent that limits NETs formation to probe mechanisms of and demonstrate a novel therapeutic approach to plaque erosion that limits endothelial damage. METHODS AND
RESULTS: We developed Collagen IV-targeted nanoparticles (Col IV NP) to deliver PAD4 inhibitors selectively to regions of endothelial cell sloughing and collagen IV-rich basement membrane exposure. We assessed the binding capability of the targeting ligand in vitro and evaluated Col IV NP targeting to areas of denuded endothelium in vivo in a mouse preparation that recapitulates features of superficial erosion. Delivery of the PAD4 inhibitor GSK484 reduced NET accumulation at sites of intimal injury and preserved endothelial continuity.
CONCLUSIONS: NPs directed to Col IV show selective uptake and delivery of their payload to experimentally eroded regions, illustrating their translational potential. Our results further support the role of PAD4 and NETs in superficial erosion. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author(s) 2021. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Neutrophil extracellular traps; Atherosclerosis; Cardiovascular nanomedicine; Experimental superficial erosion; Targeted nanoparticles

Mesh:

Substances:

Year:  2021        PMID: 33751034      PMCID: PMC8783386          DOI: 10.1093/cvr/cvab074

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  24 in total

1.  Spatiotemporal controlled delivery of nanoparticles to injured vasculature.

Authors:  Juliana M Chan; Liangfang Zhang; Rong Tong; Debuyati Ghosh; Weiwei Gao; Grace Liao; Kai P Yuet; David Gray; June-Wha Rhee; Jianjun Cheng; Gershon Golomb; Peter Libby; Robert Langer; Omid C Farokhzad
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-19       Impact factor: 11.205

2.  Targeted Nanotherapeutics Encapsulating Liver X Receptor Agonist GW3965 Enhance Antiatherogenic Effects without Adverse Effects on Hepatic Lipid Metabolism in Ldlr-/- Mice.

Authors:  Mikyung Yu; Jaume Amengual; Arjun Menon; Nazila Kamaly; Felix Zhou; Xiaoding Xu; Phei Er Saw; Seung-Joo Lee; Kevin Si; Carleena Angelica Ortega; Won Il Choi; In-Hyun Lee; Yazan Bdour; Jinjun Shi; Morteza Mahmoudi; Sangyong Jon; Edward A Fisher; Omid C Farokhzad
Journal:  Adv Healthc Mater       Date:  2017-07-21       Impact factor: 9.933

3.  NETosis, complement, and coagulation: a triangular relationship.

Authors:  Cynthia M de Bont; Wilbert C Boelens; Ger J M Pruijn
Journal:  Cell Mol Immunol       Date:  2018-03-23       Impact factor: 11.530

4.  Roles of PAD4 and NETosis in Experimental Atherosclerosis and Arterial Injury: Implications for Superficial Erosion.

Authors:  Grégory Franck; Thomas L Mawson; Eduardo J Folco; Roberto Molinaro; Victoria Ruvkun; Daniel Engelbertsen; Xin Liu; Yevgenia Tesmenitsky; Eugenia Shvartz; Galina K Sukhova; Jean-Baptiste Michel; Antonino Nicoletti; Andrew Lichtman; Denisa Wagner; Kevin J Croce; Peter Libby
Journal:  Circ Res       Date:  2018-03-23       Impact factor: 17.367

Review 5.  Temporal shifts in clinical presentation and underlying mechanisms of atherosclerotic disease.

Authors:  Gerard Pasterkamp; Hester M den Ruijter; Peter Libby
Journal:  Nat Rev Cardiol       Date:  2016-10-20       Impact factor: 32.419

6.  Targeted nanoparticles containing the proresolving peptide Ac2-26 protect against advanced atherosclerosis in hypercholesterolemic mice.

Authors:  Gabrielle Fredman; Nazila Kamaly; Stefano Spolitu; Jaclyn Milton; Devram Ghorpade; Raymond Chiasson; George Kuriakose; Mauro Perretti; Omid Farokzhad; Ira Tabas
Journal:  Sci Transl Med       Date:  2015-02-18       Impact factor: 17.956

7.  Ultra-pH-Responsive and Tumor-Penetrating Nanoplatform for Targeted siRNA Delivery with Robust Anti-Cancer Efficacy.

Authors:  Xiaoding Xu; Jun Wu; Yanlan Liu; Mikyung Yu; Lili Zhao; Xi Zhu; Sushant Bhasin; Qing Li; Emily Ha; Jinjun Shi; Omid C Farokhzad
Journal:  Angew Chem Int Ed Engl       Date:  2016-05-03       Impact factor: 15.336

8.  Inhibition of PAD4 activity is sufficient to disrupt mouse and human NET formation.

Authors:  Huw D Lewis; John Liddle; Jim E Coote; Stephen J Atkinson; Michael D Barker; Benjamin D Bax; Kevin L Bicker; Ryan P Bingham; Matthew Campbell; Yu Hua Chen; Chun-Wa Chung; Peter D Craggs; Rob P Davis; Dirk Eberhard; Gerard Joberty; Kenneth E Lind; Kelly Locke; Claire Maller; Kimberly Martinod; Chris Patten; Oxana Polyakova; Cecil E Rise; Martin Rüdiger; Robert J Sheppard; Daniel J Slade; Pamela Thomas; Jim Thorpe; Gang Yao; Gerard Drewes; Denisa D Wagner; Paul R Thompson; Rab K Prinjha; David M Wilson
Journal:  Nat Chem Biol       Date:  2015-01-26       Impact factor: 15.040

9.  A solvent-free thermosponge nanoparticle platform for efficient delivery of labile proteins.

Authors:  Won Il Choi; Nazila Kamaly; Lorena Riol-Blanco; In-Hyun Lee; Jun Wu; Archana Swami; Cristian Vilos; Basit Yameen; Mikyung Yu; Jinjun Shi; Ira Tabas; Ulrich H von Andrian; Sangyong Jon; Omid C Farokhzad
Journal:  Nano Lett       Date:  2014-10-21       Impact factor: 11.189

10.  Activation of PAD4 in NET formation.

Authors:  Amanda S Rohrbach; Daniel J Slade; Paul R Thompson; Kerri A Mowen
Journal:  Front Immunol       Date:  2012-11-29       Impact factor: 7.561

View more
  7 in total

Review 1.  Inflammation during the life cycle of the atherosclerotic plaque.

Authors:  Peter Libby
Journal:  Cardiovasc Res       Date:  2021-11-22       Impact factor: 10.787

2.  IsoLGs (Isolevuglandins) Drive Neutrophil Migration in Hypertension and Are Essential for the Formation of Neutrophil Extracellular Traps.

Authors:  Jaya Krishnan; Néstor de la Visitación; Elizabeth M Hennen; Venkataraman Amarnath; David G Harrison; David M Patrick
Journal:  Hypertension       Date:  2022-06-10       Impact factor: 9.897

Review 3.  Targeting inflammation in atherosclerosis - from experimental insights to the clinic.

Authors:  Oliver Soehnlein; Peter Libby
Journal:  Nat Rev Drug Discov       Date:  2021-05-11       Impact factor: 84.694

4.  GDF11 alleviates neointimal hyperplasia in a rat model of artery injury by regulating endothelial NLRP3 inflammasome activation and rapid re-endothelialization.

Authors:  Lei Li; Yan Gao; Zhenchuan Liu; Chenglai Dong; Wenli Wang; Kaiqin Wu; Shaorui Gu; Yongxin Zhou
Journal:  J Transl Med       Date:  2022-01-15       Impact factor: 5.531

Review 5.  Neutrophils in chronic inflammatory diseases.

Authors:  Andrea Herrero-Cervera; Oliver Soehnlein; Ellinor Kenne
Journal:  Cell Mol Immunol       Date:  2022-01-17       Impact factor: 11.530

Review 6.  Potential Role of Neutrophil Extracellular Traps in Cardio-Oncology.

Authors:  Kai-Hung Cheng; Gregory P Contreras; Ting-Yu Yeh
Journal:  Int J Mol Sci       Date:  2022-03-25       Impact factor: 5.923

Review 7.  Extracellular traps and the role in thrombosis.

Authors:  Tonglei Han; Hanfei Tang; Changpo Lin; Yang Shen; Dong Yan; Xiao Tang; Daqiao Guo
Journal:  Front Cardiovasc Med       Date:  2022-08-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.